NextCell Pharma AB
65G
Company Profile
Business description
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
Contact
Karolinska Institutet Science Park
Halsovagen 7
Huddinge14157
SWET: +46 87355595
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
24
Stocks News & Analysis
stocks
Avoid this overpriced ASX share
This ASX share is 84% overvalued and lacks a sustainable competitive advantage.
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
A broad assessment of AI’s threats and opportunities leads to moat ratings changes for more than three dozen companies.
stocks
Baidu: Moat downgraded to none from wide; AI segment growth to offset search decline in long \run
We’ve also lowered our fair value estimate of Baidu stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,942.80 | 10.30 | 0.12% |
| CAC 40 | 8,057.36 | 142.00 | 1.79% |
| DAX 40 | 23,968.63 | 559.26 | 2.39% |
| Dow JONES (US) | 47,857.06 | 116.26 | 0.24% |
| FTSE 100 | 10,412.24 | 162.72 | 1.59% |
| HKSE | 25,959.90 | 551.44 | 2.17% |
| NASDAQ | 22,697.10 | 1.16 | 0.01% |
| Nikkei 225 | 54,248.39 | 1,519.67 | 2.88% |
| NZX 50 Index | 13,213.39 | 114.56 | 0.87% |
| S&P 500 | 6,807.19 | 11.20 | 0.16% |
| S&P/ASX 200 | 8,711.40 | 7.00 | 0.08% |
| SSE Composite Index | 4,123.14 | 26.54 | 0.65% |